The global chronic obstructive pulmonary disease (COPD) treatment market by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 14,209.0 million in 2017 and is projected to exhibit a CAGR of 4.9% over the forecast period (2018–2026).

The global chronic obstructive pulmonary disease (COPD) treatment market is expected to witness significant growth over the forecast period, owing to factors such as collaborations and partnerships, mergers and acquisitions, and product launches. Active involvement by market players to improve medication adherence in COPD patients, increasing awareness about the disease, and research and development is expected to support the global chronic obstructive pulmonary disease (COPD) treatment market growth. In January 2019, ResMed Inc. announced a complete launch of its portable oxygen concentrator — Mobi — in the U.S. for chronic obstructive pulmonary disease (COPD) or other chronic diseases. Adherium, a digital health platform company focusing on improving medication adherence and patient outcomes, launched the Hailie solution in the U.S., in 2018. The Hailie solution is designed to help patients achieve better adherence by providing people who live with asthma or chronic obstructive pulmonary disease (COPD) with the tools to manage their condition. Moreover, Adherium, and Vitalus Health collaborated to combine the benefits of Adherium’s Hailie solution, and Vitalus Health provider system in 2018. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

Browse 26 Market Data Tables and 32 Figures spread through 178 Pages and in-depth TOC on Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), By Route of Administration (Oral, and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

To know the latest trends and insights prevalent in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/chronic-obstructive-pulmonary-disease-copd-treatment-market-2656

In 2018, the COPD Foundation launched the COPD Pocket Consultant Guide (PCG) app for healthcare providers which is designed to support the treatment and management of COPD. In 2018, Adherium, launched the Hailie Global Brand, which was a rebrand of the existing Smartinhaler brand and included the free Hailie app, an asthma and COPD tracking solution. In 2015, COPD Foundation launched COPD360, an innovative approach to accelerate research and develop new treatment options for chronic obstructive pulmonary disease (COPD). AstraZeneca is the founding sponsor of this initiative and COPD360 will enroll around 125,000 patients, who have agreed to share their health data, in the integrated database, giving researchers a chance to explore patient-reported outcomes and new observational data. Key Takeaways of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market:

  • The global chronic obstructive pulmonary disease (COPD) treatment market is expected to exhibit a CAGR of 9% over the forecast period (2018–2026), owing to rising prevalence of COPD and rising need for better treatment.
  • Manufacturers are focused on improving existing treatment options, research and development for new treatments, and increasing awareness efforts, which is expected to aid the market growth over the forecast period
  • Efforts by market players to improve treatment adherence, awareness of the diseases, and other such factors are expected to support the market growth over the forecast period
  • Major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner